The 2020 Basic Science Year in Review covered autoantibody origin and persistence, insights into the major histocompatibility complex and factors in rheumatoid arthritis progression and relapse.... [Read More]
Jason Liebowitz, MD, is a rheumatologist with Skylands Medical Group in Rockaway, N.J. He completed his undergraduate studies at Johns Hopkins University, Baltimore, and was inducted into Phi Beta Kappa. He attended Johns Hopkins University School of Medicine and completed his internal medicine residency at Johns Hopkins Bayview Medical Center, where he also served as a chief resident. He completed his rheumatology fellowship at Johns Hopkins University and was nominated for the 2019 Distinguished Fellow Award from the American College of Rheumatology. His research has been published in JAMA Internal Medicine, The Journal of Rheumatology, Arthritis Care and Research, The American Journal of Medicine and Medical Humanities. He greatly enjoys teaching trainees and caring for patients, which he considers a tremendous honor and privilege, and he is grateful to be able to cover medical conferences and contribute articles to The Rheumatologist.
Articles by Jason Liebowitz, MD
The 2020 ACR Review Course: Key Issues Rheumatologists Face
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.... [Read More]
Lessons from Master Clinicians: An Interview with Dr. Richard Brasington
Rheumatologists who are outstanding clinicians and provide consistent, exceptional care to patients are in the spotlight in our Lessons from a Master Clinician series. Here, we present insights from a clinician who has achieved distinction in the field of rheumatology, serving as a role model for colleagues and trainees. Richard Brasington Jr., MD, FACP, MACR,… [Read More]
A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.... [Read More]
Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors
Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.... [Read More]
ACR Introduces Draft Guideline for RA Management
Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.... [Read More]
Lessons from Master Clinicians: An Interview with Dr. Alan Baer
Rheumatologists who are outstanding clinicians and provide consistent, exceptional care to patients are in the spotlight in our Lessons from a Master Clinician series. Here, we present insights from a clinician who has achieved distinction in the field of rheumatology, serving as a role model for colleagues and trainees. Alan Baer, MD, is currently a… [Read More]
ACR Convergence 2020: COVID-19 Hyper-Inflammation in Kids
ACR CONVERGENCE 2020—Among the many ways in which the COVID-19 pandemic has changed the face of modern medicine is the emergence of multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition that shares many features of Kawasaki disease (KD). With this topic in mind, leading pediatric experts from around the world came together… [Read More]
Under Pressure: An Update on Pulmonary Hypertension
ACR CONVERGENCE 2020—In patients with connective tissue diseases, such as systemic sclerosis (SSc), pulmonary hypertension (PH) remains one of the leading causes of morbidity and mortality. In her lecture on Friday, Nov. 6, Pulmonary Hypertension: An Update, Mardi Gomberg-Maitland, MD, MSc, professor of medicine and medical director of the Pulmonary Hypertension Program at The George… [Read More]
The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?
ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held… [Read More]
- 1
- 2
- 3
- …
- 5
- Next Page »